Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | MB | P02144 | 1/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | RARG | P13631 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8648800 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL8643836 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL104524 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL14463078 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL27254651 | 0.81 | SMN1; SMN2 (0.64) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL11526208 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL11355701 | 0.81 | MAPT (0.56) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL18509213 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL8811830 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL19806131 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTL3MBTL1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2017-10-12 | — | — | US | disclosed |
| US-8008487-B2 | Substituted thieno[2,3-D]pyrimidines as fungicides | DOW AGROSCIENCES LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008487-B2 | Substituted thieno[2,3-D]pyrimidines as fungicides | DOW AGROSCIENCES LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| CN-101035537-A | Compositions and methods for treating ocular diseases | MERCK & CO INC (US) | 2007-09-12 | — | — | CN | disclosed |
| US-6127388-A | Azetidine, pyrrolidine and piperidine derivatives as 5-HT1D receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 2000-10-03 | — | — | US | disclosed |
| US-6025374-A | Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists | MERCK SHARP & DOHME, LTD. (GB) | 2000-02-15 | — | — | US | disclosed |
| US-5998440-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARPE & DOHME LTD. (GB) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | CXCL12, CXCR4, CX3CR1 | SMN1; SMN2 3977/4885HTT 3230/4885L3MBTL1 4795/4885 |
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | ENY2, ENO1, IDH1 | SMN1; SMN2 3027/4885HTT 664/4885L3MBTL1 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.